UK-based NRG Therapeutics secured £50 million ($67 million) in an oversubscribed Series B round to advance its small-molecule regulators of the mitochondrial permeability transition pore (mPTP) towards clinical testing in ALS and Parkinson’s disease. Backed by notable venture arms including Merck KGaA and Novartis, the funding supports exploratory human trials slated for next year. These mitochondrial therapies represent promising candidates addressing fundamental neurodegenerative disease mechanisms.